The study of clinical effectiveness and safety of a combination of 0.4% minoxidil and 0.05% retinaldehyde nanoparticles solution for treatment of androgenetic alopecia

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20201104003

Enrollment

Registered

2020-11-04

Start date

2020-11-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia Androgenetic Alopecia Female pattern hair loss Topical nanominoxidil Topical retinaldehyde nanoparticles

Interventions

combination of 0.4% minoxidil and 0.05% retinaldehyde nanoparticles solution

Experimental Drug

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patient with androgenetic alopecia with Norwood-Hamilton grade 3-4 or Ludwig 2.Volunteers who have well adherence and can be followed up as appointed grade 1-2

Exclusion criteria

Exclusion criteria: 1.Prior treatment of androgenetic alopecia with topical therapy within 3 months 2.Prior treatment of androgenetic alopecia with oral therapy within 6 months 3.Prior treatment of androgenetic alopecia with hair transplantation within 12 months 4.Pregnancy or breastfeeding 5.Hirsutism 6.Abnormal thyroid function 7.Iron deficiency anemia 8.Patient recieved contraception or hormone replacement therapy

Design outcomes

Primary

Measure	Time frame
number of hair week 0,12,24 hair count with tricoscale	—

Secondary

Measure	Time frame
Quality of life Week 0,12,24 Questionnaire,Side effect Week 0,12,24 Questionnaire	—

Countries

Thailand

Contacts

Public ContactRatchathorn Panchaprateep

Faculty of Medicine, Chulalongkorn University

rpanchaprateep@gmail.com0898923819

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026